Skip to main content
Caplight Logo









ZOE

ZOE

Private
LondonHealthcare & Life Scienceshttps://zoe.com/en-us

Last Round

Series B

Apr 30, 2025

Est. Valuation

$332.5M

Total Funding Raised

$138.81M

Company Overview

ZOE is a nutrition science company that provides personalized dietary plans and health insights through at-home medical testing services analyzing gut microbiome, blood fat, and blood sugar responses.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, D2C Brands, Subscription Commerce, Sports & Fitness

Business Model

B2C

Customer Profile

Subscription SaaS, Hardware Sales

AI Layer

Application

Keywords

personalized nutritiongut microbiome testingmetabolic healthat-home health testbiohackingcontinuous glucose monitorCGMprecision nutritionDTC healthdigital health appweight managementnutrigenomicspreventative healthwellness tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ZOE Comparables

Compare ZOE with similar companies based on industry and business-model similarity.

ZOE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Viome Life Sciences
84%
Levels
83%
Signos
79%

ZOE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 30, 2025
Series B ExtensionJul 29, 2024
Series B ExtensionMar 15, 2023
Series B ExtensionDec 1, 2022
Series BMay 4, 2021
Series A
Jun 1, 2019

ZOE Investors

Notable investors and investment history

ZOE investors
InvestorRounds
Coefficient CapitalSeries B Extension
AccompliceSeries A, Series B, Series B Extension
Falcon Wealth PlanningSeries B
DaphniSeries A, Series B, Series B Extension
L CattertonSeries B Extension
Sageview CapitalSeries B
THVCSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    Monthly visitors grew 49% MoM, reaching 18.8K.

  • Jan 8, 2026

    Monthly visitors grew 482% MoM, reaching 12.6K.

ZOE Filings

Explore SEC and related filing metadata, where available.

ZOE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ZOE's valuation, stock price, and market status.

Is ZOE a public or private company?

ZOE is a private company.

What is the current stock price of ZOE?

ZOE is a private company with no public stock price. No recent secondary market data is available.

How much is ZOE worth (valuation)?

ZOE's valuation is estimated at $250.0M based on funding round data.

Can I buy ZOE stock?

ZOE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ZOE's last funding round?

ZOE's most recent funding round was Series B on July 29, 2024.

Who are the main investors in ZOE?

Key investors in ZOE include Coefficient Capital, Accomplice, Sageview Capital, Ahren Innovation Capital.

Will ZOE IPO soon?

No public IPO plans have been announced for ZOE.

How can I track ZOE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ZOE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range145
Year Founded2017
Last FundingApr 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?